Abstract:3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR) catalyzes the formation of mevalonate. In many classes of organisms, this is the committed step leading to the synthesis of essential compounds, such as cholesterol. However, a high level of cholesterol is an important risk factor for coronary heart disease, for which an effective clinical treatment is to block HMGR using inhibitors like statins. Recently the structures of catalytic portion of human HMGR complexed with six different statins have been determined by a delicate crystallography study (Istvan and Deisenhofer Science 2001, 292, 1160-1164), which established a solid basis of structure and mechanism for the rational design, optimization, and development of even better HMGR inhibitors. In this study, three-dimensional quantitative structure-activity relationship (3D QSAR) with comparative molecular field analysis (CoMFA) was performed on a training set of up to 35 statins and statin-like compounds. Predictive models were established by using two different ways: (1) Models-fit, obtained by SYBYL conventional fit-atom molecular alignment rule, has cross-validated coefficients (q2) up to 0.652 and regression coefficients (r2) up to 0.977. (2) Models-dock, obtained by FlexE by docking compounds into the HMGR active site, has cross-validated coefficients (q2) up to 0.731 and regression coefficients (r2) up to 0.947. These models were further validated by an external testing set of 12 statins and statin-like compounds. Integrated with CoMFA 3D QSAR predictive models, molecular surface property (electrostatic and steric) mapping and structure-based (both ligand and receptor) virtual screening have been employed to explore potential novel hits for the HMGR inhibitors. A representative set of eight new compounds of non-statin-like structures but with high pIC(50) values were sorted out in the present study.

A 3D-QSAR Study on a Novel Chromanol Class of Iks Potassium Channel Blockers

Structure-based Rational Quest for Potential Novel Inhibitors of Human HMG-CoA Reductase by Combining CoMFA 3D QSAR Modeling and Virtual Screening.

Quantitative Structure–activity Relationship: Promising Advances in Drug Discovery Platforms

3D-QSAR Study on 2,3-Dihydroimidazo[4,5]-pyridin-2-one Derivatives with a Meta Substitution Pattern As V600E BRAF Inhibitors

Three-Dimensional Quantitative Structure−Activity Relationship Analysis of the New Potent Sulfonylureas Using Comparative Molecular Similarity Indices Analysis

3D-QSAR Study for Inhibitors of Cyclin-Dependent Kinase 4

Design and Synthesis of Novel Potassium Channel Openers and QSAR Studies

Three-dimensional quantitative structure–activity relationship study for analogues of TQXs using CoMFA and CoMSIA

3D-QSAR Studies on AChE Inhibitory Activities of 2-Phenoxy-indan-1-one Derivatives

Three-Dimensional Quantitative Structure-Activity Relationship Analyses of A Series of Butenolide Eta Antagonists

Studies on the 3D-Qsar of Novel 1-Aryl-1, 4-Dihydro-3-acylhydrazinocarbonyl-6-methyl-4-pyridazinones

3D Qsar Studies on Gsk-3 Inhibition by Aloisines

Toward the identification of a reliable 3D QSAR pharmacophore model for the CCK2 receptor antagonism

3D-QSAR Studies of 2,4-Thiazolidinediones As Aldose Reductase Inhibitors Using CoMFA,CoMSIA and Molecular Docking

Structure-based 3D-QSAR Studies on Thiazoles As 5-HT3 Receptor Antagonists

Three-dimensional Quantitative Structure–activity Relationship Study on Paullones As CDK Inhibitors Using CoMSIA and CoMFA

QSAR Analysis of Human Adenosine A3 Receptor Antagonists

Structure-based 3D-QSAR studies on heteroarylpiperazine derivatives as 5-HT3 receptor antagonists.

Qsar of Pyrazole Oxadiazole Derivatives As S1p1 Agonists Studied by Comfa, Comsia and Docking

3D-QSAR and 3D-QSSR Studies of Thieno[2,3-D]pyrimidin-4-yl Hydrazone Analogues As CDK4 Inhibitors by CoMFA Analysis

3D-QSAR Analysis of Sialyltransferase Inhibitors